AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2026
Feb 11, 2026
31900_dirs_2026-02-11_5cae5b93-81f5-45da-9a9a-dad334acdc72.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2026-02-05
Reporting Person: Francis Chris (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-05 | Ordinary Shares | A | 38750 | $0.00 | Acquired | 63750 | Direct |
| 2026-02-09 | Ordinary Shares | S | 1883 | $13.45 | Disposed | 61867 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-05 | Share Option (right to buy) | $12.75 | A | 232500 | Acquired | 2036-02-05 | Ordinary Shares (232500) | Direct |
Footnotes
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2: On February 9, 2026, the reporting person sold 1,883 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.